Abstract
Here we represent resources available, including FDA web sites, for information on the drug approval process and Critical Path Initiatives. We include information on the cost of clinical drug development, approved drugs since 1995, the largest pharmaceutical companies based on pharmaceutical sales, the top selling drugs in 2009, and the approved drugs in the first half of 2010.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CDER:
-
Center for Drug Evaluation and Research
- CPI:
-
Critical Path Initiative
- IND:
-
Investigational new drug
- NDA:
-
New drug application
References
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Khojasteh, S.C., Wong, H., Hop, C.E.C.A. (2011). Approved Drugs. In: Drug Metabolism and Pharmacokinetics Quick Guide. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5629-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-4419-5629-3_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-5628-6
Online ISBN: 978-1-4419-5629-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)